2026 Q2 -tulosraportti
35 päivää sitten
‧21 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 30.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 17.7. | ||
2026 Q1 -tulosraportti 5.5. | ||
2025 Q4 -tulosraportti 20.2. | ||
2025 Q3 -tulosraportti 24.10.2025 | ||
2025 Q2 -tulosraportti 26.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3.8.Some get fast tracks...... https://www.nordnet.se/marknaden/nyheter/748c6f58-873d-493c-b9cd-bdfe678c8f66
·31.7.this company, along with Alligator, are the biggest failures in many many years. Again and again they raise money from us, and they haven't gotten closer to a product or sales that make a difference. The only thing they have succeeded with is that the management/board has secured themselves a princely salary for several years at our expense WITHOUT GETTING CLOSER TO ANYTHING WE INVESTORS CAN USE FOR ANYTHING. Ugh, how ashamed I would be if I were part of that conspiracy. And yes, I have many shares in both companies with a loss of around 500,000 thousand. I know I could have just sold out years ago and that I'm the one who pressed the buy button, but one is naive and hopes it turns around and that they will act like adult professionals. But they haven't managed that, and hence my long post from a many-year investor who is bitter and disappointed. Have a good weekend to others who are in the same situation.LP; Unfortunate development for you. I myself am 52.89% down but obviously didn't invest your volume. But I entered a number of pharmaceutical companies to test the market and can report that with the exception of Camurus, they are bad investments so far out of 8 different companies. But as I said, a bit of a test but still quite many thousands down but diversified risk which was my plan, something, maybe a couple, will do well and the rest so-so to worse...... Have a fantastic weekend for now because on Monday it's "New balls of fire..." again... 😉
·28.6.Is it correct that they have an FDA approval October 29?
6.7."Xbrane Biopharma AB (publ) (“Xbrane” or “the Company”) (Nasdaq Stockholm: XBRANE) receives FDA BsUFA date of October 29, 2026 for its investigational biosimilar candidate to LUCENTIS® (ranibizumab)" (https://mfn.se/a/xbrane-biopharma/xbrane-biopharma-ab-publ-xbrane-or-the-company-nasdaq-stockholm-xbrane-receives-fda-bsufa-date-of-october-29-2026-for-its-investigational-biosimilar-candidate-to-lucentis-r-ranibizumab)- ·25.6.Hello all pessimists, I see that the interest in this forum is low, but if we look at the message that the FED is holding back, it concerns Lucentis which the EU has already approved. How do we then view the risk that the Yanks do not approve this? The only thing would be that they do it due to protecting their own companies, otherwise it will obviously be an OK in the autumn. Personally, I will wait a bit more in case worried souls sell at a price acceptable to me, and then I will buy more, not least to lower my GAV. So go my thoughts.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
35 päivää sitten
‧21 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3.8.Some get fast tracks...... https://www.nordnet.se/marknaden/nyheter/748c6f58-873d-493c-b9cd-bdfe678c8f66
- ·31.7.this company, along with Alligator, are the biggest failures in many many years. Again and again they raise money from us, and they haven't gotten closer to a product or sales that make a difference. The only thing they have succeeded with is that the management/board has secured themselves a princely salary for several years at our expense WITHOUT GETTING CLOSER TO ANYTHING WE INVESTORS CAN USE FOR ANYTHING. Ugh, how ashamed I would be if I were part of that conspiracy. And yes, I have many shares in both companies with a loss of around 500,000 thousand. I know I could have just sold out years ago and that I'm the one who pressed the buy button, but one is naive and hopes it turns around and that they will act like adult professionals. But they haven't managed that, and hence my long post from a many-year investor who is bitter and disappointed. Have a good weekend to others who are in the same situation.LP; Unfortunate development for you. I myself am 52.89% down but obviously didn't invest your volume. But I entered a number of pharmaceutical companies to test the market and can report that with the exception of Camurus, they are bad investments so far out of 8 different companies. But as I said, a bit of a test but still quite many thousands down but diversified risk which was my plan, something, maybe a couple, will do well and the rest so-so to worse...... Have a fantastic weekend for now because on Monday it's "New balls of fire..." again... 😉
- ·28.6.Is it correct that they have an FDA approval October 29?6.7."Xbrane Biopharma AB (publ) (“Xbrane” or “the Company”) (Nasdaq Stockholm: XBRANE) receives FDA BsUFA date of October 29, 2026 for its investigational biosimilar candidate to LUCENTIS® (ranibizumab)" (https://mfn.se/a/xbrane-biopharma/xbrane-biopharma-ab-publ-xbrane-or-the-company-nasdaq-stockholm-xbrane-receives-fda-bsufa-date-of-october-29-2026-for-its-investigational-biosimilar-candidate-to-lucentis-r-ranibizumab)
- ·25.6.Hello all pessimists, I see that the interest in this forum is low, but if we look at the message that the FED is holding back, it concerns Lucentis which the EU has already approved. How do we then view the risk that the Yanks do not approve this? The only thing would be that they do it due to protecting their own companies, otherwise it will obviously be an OK in the autumn. Personally, I will wait a bit more in case worried souls sell at a price acceptable to me, and then I will buy more, not least to lower my GAV. So go my thoughts.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 30.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 17.7. | ||
2026 Q1 -tulosraportti 5.5. | ||
2025 Q4 -tulosraportti 20.2. | ||
2025 Q3 -tulosraportti 24.10.2025 | ||
2025 Q2 -tulosraportti 26.8.2025 |
2026 Q2 -tulosraportti
35 päivää sitten
‧21 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 30.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 17.7. | ||
2026 Q1 -tulosraportti 5.5. | ||
2025 Q4 -tulosraportti 20.2. | ||
2025 Q3 -tulosraportti 24.10.2025 | ||
2025 Q2 -tulosraportti 26.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3.8.Some get fast tracks...... https://www.nordnet.se/marknaden/nyheter/748c6f58-873d-493c-b9cd-bdfe678c8f66
- ·31.7.this company, along with Alligator, are the biggest failures in many many years. Again and again they raise money from us, and they haven't gotten closer to a product or sales that make a difference. The only thing they have succeeded with is that the management/board has secured themselves a princely salary for several years at our expense WITHOUT GETTING CLOSER TO ANYTHING WE INVESTORS CAN USE FOR ANYTHING. Ugh, how ashamed I would be if I were part of that conspiracy. And yes, I have many shares in both companies with a loss of around 500,000 thousand. I know I could have just sold out years ago and that I'm the one who pressed the buy button, but one is naive and hopes it turns around and that they will act like adult professionals. But they haven't managed that, and hence my long post from a many-year investor who is bitter and disappointed. Have a good weekend to others who are in the same situation.LP; Unfortunate development for you. I myself am 52.89% down but obviously didn't invest your volume. But I entered a number of pharmaceutical companies to test the market and can report that with the exception of Camurus, they are bad investments so far out of 8 different companies. But as I said, a bit of a test but still quite many thousands down but diversified risk which was my plan, something, maybe a couple, will do well and the rest so-so to worse...... Have a fantastic weekend for now because on Monday it's "New balls of fire..." again... 😉
- ·28.6.Is it correct that they have an FDA approval October 29?6.7."Xbrane Biopharma AB (publ) (“Xbrane” or “the Company”) (Nasdaq Stockholm: XBRANE) receives FDA BsUFA date of October 29, 2026 for its investigational biosimilar candidate to LUCENTIS® (ranibizumab)" (https://mfn.se/a/xbrane-biopharma/xbrane-biopharma-ab-publ-xbrane-or-the-company-nasdaq-stockholm-xbrane-receives-fda-bsufa-date-of-october-29-2026-for-its-investigational-biosimilar-candidate-to-lucentis-r-ranibizumab)
- ·25.6.Hello all pessimists, I see that the interest in this forum is low, but if we look at the message that the FED is holding back, it concerns Lucentis which the EU has already approved. How do we then view the risk that the Yanks do not approve this? The only thing would be that they do it due to protecting their own companies, otherwise it will obviously be an OK in the autumn. Personally, I will wait a bit more in case worried souls sell at a price acceptable to me, and then I will buy more, not least to lower my GAV. So go my thoughts.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt